… In summary, DELIVER will determine whether dapagliflozin compared with … of cardiovascular
death or worsening heart failure in patients with HFpEF or HFmrEF. DELIVER will provide …

… of heart failure hospitalization and worse health status. Treatment with dapagliflozin improves
cardiovascular … to greater symptom improvement in patients with obesity, compared with …

… We found that in patients with HFimpEF enrolled in the DELIVER trial, dapagliflozin reduced
the composite of cardiovascular death or worsening HF events, and other outcomes, to a …

… patients with heart failure and a left ventricular ejection fraction of more than 40% to receive
dapagliflozin (… The primary outcome was a composite of worsening heart failure (which was …

… tolerability of dapagliflozin according to frailty status in patients with heart failure with mildly
reduced or preserved ejection fraction randomized in DELIVER (Dapagliflozin Evaluation to …

… et al; DELIVER Trial Committees and Investigators. Dapagliflozin in heart failure with mildly
reduced or … Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.  …

… In patients with heart failure and mildly reduced or preserved ejection fraction … in DELIVER,
dapagliflozin reduced the combined risk of cardiovascular death or worsening heart failure …

… In this prespecified analysis of the DELIVER trial, we evaluated the time course of benefits
of dapagliflozin on clinically relevant outcomes in patients with HF with mildly reduced or …

… and mortality outcomes in patients with heart failure regardless of ejection fraction is … two
trials testing dapagliflozin in participants with heart failure and different ranges of left ventricular …

… et al; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart
failure and … Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.  …